Histogen Aesthetics, a subsidiary of regenerative medicine company Histogen, Inc., has acquired the CellCeuticals Biomedical Skin Treatments line of skin care products.
Histogen Aesthetics said it will continue sales of the 11 existing CellCeuticals Biomedical Skin Treatments skin care products, while bringing new innovation to the line through the addition of a unique regenerative medicine technology, working to improve skin aging at a cellular level.
“We have long admired the science, clinical data and elegant formulas behind the CellCeuticals line, and see it as an ideal fit for our recently revitalized aesthetics subsidiary,” said Dr. Gail K. Naughton, CEO and chairman of Histogen, Inc. “We are very excited to begin infusing unique cell-signaling factors into the CellCeuticals regimen, to truly transform skin one cell at a time.”
“I am pleased that the CellCeuticals Biomedical Skin Treatments will evolve, and see Histogen Aesthetics as an excellent home for this innovative product line,” added Paul Scott Premo, co-founder of CellCeuticals Skin Care, Inc. “I believe the addition of this regenerative medicine technology will be the opportunity to introduce a new generation of products that are the vanguard of regenerative skin care.”
CellCeuticals is currently available at retailers including QVC.com Dermstore.com, Nordtsrom.com and its own shop, cellceuticalskincare.com.